Phase 2 study of ABT-510 in patients with previously untreated advanced renal cell carcinoma

Clinical Cancer Research

Volumn 13, Issue 22, 2007, Pages 6689-6695

  Ebbinghaus, Scot ^a,h   Hussain, Maha ^b   Tannir, Nizar ^c   Gordon, Michael ^d   Desai, Apurva A ^e   Knight, Raymond A ^f   Humerickhouse, Rod A ^f   Qian, Jiang ^f   Gordon, Gary B ^f   Figlin, Robert ^g  

^a UNIVERSITY OF ARIZONA   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d Premiere Oncology of Arizona   (United States)

^e UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^f ABBOTT LABORATORIES   (United States)

^g CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^h MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BEVACIZUMAB; ERLOTINIB; N ACETYLSARCOSYLGLYCYLVALYL DEXTRO ALLOISOLEUCYLTHREONYLNORVALYLISOLEUCYLARGINYLPROLINE ETHYLAMIDE; SORAFENIB; SUNITINIB; TEMSIROLIMUS;

ADULT; ADVANCED CANCER; AGED; ALBUMIN BLOOD LEVEL; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANOREXIA; ARTICLE; BILIRUBIN BLOOD LEVEL; BLEEDING; BONE METASTASIS; BRAIN HEMORRHAGE; CALCIUM BLOOD LEVEL; CANCER PATIENT; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DECREASED APPETITE; DEEP VEIN THROMBOSIS; DEHYDRATION; DRUG ACTIVITY; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FATIGUE; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEADACHE; HEMOGLOBIN BLOOD LEVEL; HEMOPTYSIS; HUMAN; HUMAN TISSUE; HYPERGLYCEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; HYPOPHOSPHATEMIA; INCIDENCE; INJECTION SITE CONTUSION; INJECTION SITE IRRITATION; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INJECTION SITE REACTION; INJECTION SITE URTICARIA; KIDNEY CARCINOMA; LIVER METASTASIS; LUNG METASTASIS; LYMPHOCYTE COUNT; MALE; NAUSEA; NECK PAIN; NEUTROPHIL COUNT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PHOSPHATE BLOOD LEVEL; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SODIUM BLOOD LEVEL; THROMBOCYTE COUNT;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; CARCINOMA, RENAL CELL; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; OLIGOPEPTIDES; TREATMENT OUTCOME;

EID: 36749060830     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-1477     Document Type: Article

References (25)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007;57:43-66.
2. Linehan WM, Zbar B, Bates SE, Zelefsky MJ, Yang JC. Cancer of the kidney and ureter. In: DeVita VT, Jr., Hellman S, Rosenberg SA, editors. Cancer: principles & practice of oncology. 6th ed. New York: Lippincott Williams & Wilkins; 2001.p .1362-96.
3. Schoffski P, Dumez H, Clement P, Hoeben A, Prenen H, Wolter P. Emerging role of tyrosine kinase inhibitors in the treatment of advanced renal cell cancer: a review. Ann Oncol 2006;17:1185-96.
4. Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003;349:427-34.
5. Hainsworth JD, Sosman JA, Spigel DR, Edwards DL, Baughman C, Greco A. Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib. J Clin Oncol 2005;23:7889-96.
6. Motzer RJ, Michaelson MD, Redman BG, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006;24:16-24.
7. Motzer RJ, Rini BI, Bukowski RM, et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006;295:2516-24.
8. Ratain MJ, Eisen T, Stadler WM, et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2006;24:2505-12.
9. Patel PH, Chaganti RS, Motzer RJ. Targeted therapy for metastatic renal cell carcinoma. Br J Cancer 2006;94:614-9.
10. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356:125-34.
11. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon α in metastatic renal-cell carcinoma. N Engl J Med 2007;356:115-24.
12. Lawler J. The structural and functional properties of thrombospondin. Blood 1986;67:1197-209.
13. Dameron KM, Volpert OV, Tainsky MA, Bouck N. Control of angiogenesis of fibroblasts by p53 regulation of thrombospondin-1. Science 1994;165:1582-4.
14. Volpert OV, Tolsma SS, Pellerin S, et al. Inhibition of angiogenesis by thrombospondin-1. Biochem Biophys Res Commun 1995;217:326-32.
15. Hoekstra R, de Vos FY, Eskens FA, et al. Phase I safety, pharmacokinetic, and pharmacodynamic study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 in patients with advanced cancer. J Clin Oncol 2005;23:5188-97.
16. Hoekstra R, de Vos FY, Eskens FA, et al. Phase I study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 with 5-fluorouracil and leucovorin: A safe combination. Eur J Cancer 2006;42:467-72.
17. Gordon MS, Mendelson D, Guirguis MS, et al. ABT-510, an anti-angiogenic, thrombospondin-1 (TSP-1) mimetic peptide, exhibits favorable safety profile and early signals of activity in a randomized phase IB trial [abstract 780]. Proc Am Soc Clin Oncol 2003;22:195.
18. Carr RA, Marsh K, Schneider A, et al. Pharmacokinetic/pharmacodynamic (PK/PD) relationships for the angiogenesis inhibitor ABT-510 in preclinical efficacy models [abstract 250]. Eur J Cancer 2002;38 Suppl 7:S79.
19. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205-16.
20. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
21. Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M. Interferon-α as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002;20:289-96.
22. Atkins MB, Hidalgo M, Stadler WM, et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 2004;22:909-18.
23. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon α, or both for advanced renal-cell carcinoma. N Engl J Med 2007;356:2271-81.
24. Baker L, Demetri GD, Mendelson DS, et al. A randomized phase 2 study of the thrombospondinmimetic peptide ABT-510 in patients with advanced soft tissue sarcoma (STS). J Clin Oncol 2005;23 Suppl:819s. Abstract 9013.
25. McKeegan EM, Carlson D, Knight R, et al. Characterization of human circulating endothelial cells to monitor response to antitumor therapy in human clinical trials. Presented at the First AACR International Conference on Molecular Diagnostics in Cancer Therapeutic Development, September 12-15, 2006; Chicago, IL. Abstract PR-5. Available at : http://www.aacrmeetingabstracts.org/ cgi/gca?allch=&SEARCHID=1&AUTHOR1=mckeegan&FIRSTINDEX=0&hits= 10&RESULTFORMAT=1&gca=aacrmtg%3B2006%2F2%2FPR-5. Accessed July 31, 2007.